Healthcare Global Enterprises Limited (HCG) announced the introduction and adoption of the HCG Employee Stock Option Scheme 2026 (HCG ESOS 2026). This decision was made by the Board of Directors at their meeting held on Thursday, February 05, 2026, based on the recommendation of the Nomination and Remuneration Committee. The ESOP Scheme is in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The scheme allows for a maximum of 74,21,455 stock options to be granted. The exercise price for options granted on or before June 30, 2026, is set at ₹495. For options granted after this date, the exercise price will be determined by the Nomination and Remuneration Committee, but will not be less than ₹495. The introduction and adoption of the HCG ESOS 2026 are subject to the shareholders' approval. Further details, as required by SEBI regulations, will be provided in the explanatory statement for the shareholders' meeting. The scheme will be administered by the Committee, with vesting periods determined by the NRC, ranging from a minimum of one year to a maximum of seven years from the grant date. The meeting commenced at 12 noon and concluded at 7:35 p.m. IST.
